Mbx Biosciences Inc Quick Ratio (MBX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Mbx Biosciences Inc   (NASDAQ: MBX)

Mbx Biosciences Inc 's Quick Ratio

MBX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 19.14 below Mbx Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Quick Ratio than Mbx Biosciences Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 150, from total ranking in the second quarter 2026 at 256.

Explain Quick Ratio?
How much Cash & cash equivalents MBX´s has?
What are MBX´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MBX/financial-strength
https://api.csimarket.com/api/v1/companies/MBX/fundamentals
https://api.csimarket.com/api/v1/companies/MBX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
MBX Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 108.65 %
Y / Y Cash & cash equivalent Change 22.96 %
Quick Ratio MRQ 19.14
MBX's Total Ranking # 150
Seq. Current Liabilities Change 6.37 %
Seq. Cash & cash equivalent Change -38.5 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 46
Healthcare Sector # 68
Overall Market # 242


Quick Ratio Statistics
High Average Low
33.1 24.43 13.71
(Jun 30 2026)   (Dec 31 2023)




Financial Statements
Mbx Biosciences Inc 's Current Liabilities $ 25 Millions Visit MBX's Balance sheet
Mbx Biosciences Inc 's Cash & cash equivalent $ 482 Millions Visit MBX's Balance sheet
Source of MBX's Sales Visit MBX's Sales by Geography


Cumulative Mbx Biosciences Inc 's Quick Ratio

MBX's Quick Ratio for the trailling 12 Months

MBX Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 74.61 %
Y / Y Cash & cash equivalent TTM Growth 85.65 %
Quick Ratio TTM 26.35
Total Ranking TTM # 3173
Seq. Current Liabilities TTM Growth 19.92 %
Seq. Cash & cash equivalent TTM Growth 4.52 %


  News about Mbx Biosciences Inc Quick Ratio

MBX Biosciences Advances Hypoparathyroidism Treatment with Successful Enrollment in Phase 2 Avail Trial of Canvuparat...

Advancement in Hypoparathyroidism Treatment: MBX Biosciences’ Phase 2 Avail Trial of MBX 2109 Concludes Enrollment MBX Biosciences has reached a significant milestone in the development of its promising treatment for hypoparathyroidism with the completion of participant enrollment in the Phase 2 Avail trial for MBX 2109, also known as Canvuparatide. With the number of enrollees surpassing the initial target, the trial is poised to provide crucial data that could potentially change the landscape of treatment for patients suffering from this challenging endocrine disorder. Topline results from the trial are anticipated in the third quarter of 2025. Understanding HypoparathyroidismHypoparathyroidism is a rare condition characterized by insufficient production of the parathyroid hormone (PTH), which plays a pivotal role in maintaining calcium and phosphorus balance in the body. This deficiency can lead to a variety of symptoms, including muscle cramps, tingling or burning sensations in the fingertips, toes, and lips, as well as more severe complications like cardiac arrhythmias and seizures. Current treatment options mainly focus on managing symptoms by supplementing calcium and vitamin D, but they do not address the underlying hormone deficiency.


On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $25.17 millions, cumulative Quick Ratio decreased to 26.35 above the MBX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Mbx Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2646 to 3173.

Explain Quick Ratio?
How much Cash & cash equivalents MBX´s has?
What are MBX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 412
Healthcare Sector # 832
Within the Market # 3173


trailing twelve months Quick Ratio Statistics
High Average Low
11.59 7.67 5.7
(Jun 30 2026)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Rallybio Corporation  51.94 $ 90.693  Millions$ 1.746  Millions
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Vyne Therapeutics Inc   41.29 $ 268.860  Millions$ 6.511  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Xbiotech Inc   39.02 $ 105.037  Millions$ 2.692  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions

Date modified: 2026-11-11T13:51:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.